Nutra Pharma Corp., a biotechnology holding company, announced today that its minority owned subsidiary, ReceptoPharm Inc., has achieved a milestone in investigating their lead drug compound's effects against HIV.
ReceptoPharm reported to Nutra Pharma that it has completed its primary investigation into the efficacy of their drug, RPI-MN against HIV. The drug proved to be an effective blocker of the two most important viral isolates that are involved in primary infection of the host and the destruction of T-cells. The mechanism of action appears to be unique and is under investigation.
The tests were conducted by two independent laboratories at the Northwestern University (Chicago) and the University of California (San Diego) respectively. ReceptoPharm is continuing the laboratory studies to establish if RPI-MN has particular attributes that would support its accelerated entry into clinical trials for the treatment of HIV and AIDS. The Company is now focused on moving these products from their R&D phase into controlled regulatory trials.
"We now have solid evidence that ReceptoPharm's lead drug should be effective in HIV patients," said Rik Deitsch, Nutra Pharma's Chief Executive Officer. "ReceptoPharm will now focus on moving the drug through controlled human trials," he added.
"These studies have further corroborated earlier work provided by Nutra Pharma on the similar drug, Immunokine," commented Paul F. Reid, Ph.D., ReceptoPharm's Chief Executive Officer. "We have been very satisfied with the synergies we've found between our two companies that we hope will now lead to the rapid initiation of clinical studies in several diseases that are currently without satisfactory treatment options," he added. Dr. Reid obtained his Doctorate in Neurobiology from Imperial College, London and has worked at the United States Army Medical Research Institute for Infectious Diseases (USAMRIID), at Fort Detrick, Maryland.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Completing ReceptoPharm's HIV in-vitro studies should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.